Global law firm White & Case LLP has advised New Alvogen Group Holdings, Inc., the parent company of Alvogen Pharma US, Inc. ("Alvogen"), on the entry into a definitive agreement to sell the parent company to Lotus Pharmaceutical Co., Ltd.
The agreement builds upon the existing long-standing collaboration between Alvogen and Lotus, including several highly successful co-developed product launches, and gives Lotus access to a US platform, including a dedicated salesforce, in-house manufacturing at Alvogen's Norwich, New York facility and a complementary R&D pipeline.
Alvogen is a privately owned company focused on developing, in-licensing, manufacturing and marketing pharmaceutical products.
The White & Case team was led by M&A partners Oliver Brahmst, Daniel Kozin and Kathrin Schwesinger (all in New York), and included M&A partners Lucy Bullock, James Turner (both London) and Thomas Glauden (Luxembourg) and associates Chris Hebert (Miami), Ty Akkoyun and Nadim Dabbous (both New York); Debt Finance partners Justin Wagstaff and Elizabeth Kirk and associate Shana Vantusko (all in New York); Tax partner Scott Fryman (New York); Life Science and Healthcare Regulatory partner Bethany Hills (New York); Sustainability & Responsible Business partner Taylor Pullins (Houston) and associate Taylor Gillespie (New York); Employment, Compensation & Benefits partner Tal Marnin and associate Peter Shelburne (New York); and Technology Transactions partner Arlene Arin Hahn (New York) and counsel Ajita Shukla (Washington, DC). Law clerk Alexia Kavaleff (New York) also assisted on the matter.
Press contact
For more information please speak to your local media contact.
